<DOC>
	<DOCNO>NCT00005815</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide may stop growth melanoma stop blood flow tumor . Combining chemotherapy thalidomide may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness temozolomide plus thalidomide treating patient stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Temozolomide Thalidomide Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) temozolomide use extend continuous schedule combination thalidomide patient advanced melanoma . - Determine response rate combination use extend continuous schedule MTD 30 patient advanced metastatic melanoma without brain metastasis 15 patient metastatic melanoma brain . - Further characterize safety toxicity combination patient . OUTLINE : This dose escalation study temozolomide ( phase I ) follow response rate determination study ( phase II ) . Patients receive oral temozolomide daily 6 week follow 2-4 week rest . Patients receive oral thalidomide daily entire 8-10 week course . Treatment continue absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Once MTD determine , additional patient accrue receive treatment temozolomide thalidomide recommend phase II dose . PROJECTED ACCRUAL : A total 3-24 patient accrued phase I additional 45 patient ( 15 CNS disease , 30 without CNS disease ) accrue phase II study within 18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic malignant melanoma consider unresectable Stage III IV ocular , mucosal , cutaneous melanoma Measurable disease No CNS disease ( phase I ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT/SGPT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No history active angina No myocardial infarction within past 6 month No history significant ventricular arrhythmia require medication antiarrhythmic Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 4 week study No frequent vomit medical condition could interfere oral medication intake ( e.g. , partial bowel obstruction ) No preexist neurotoxicity grade 2 great No serious concurrent infection treat antibiotic No nonmalignant medical illness uncontrolled whose control may jeopardize complication study No psychiatric disorder would preclude study compliance No medical condition reason would preclude study No malignancy within past 2 year except : Nonmelanoma skin cancer Carcinoma situ cervix History T1a b prostate cancer detect incidentally TURP comprise less 5 % resect tissue PSA normal since TURP No AIDS relate illness HIV negative PRIOR CONCURRENT THERAPY : Recovered prior therapy Biologic therapy : At least 4 week since prior biologic therapy At least 4 week since prior immunotherapy No concurrent immunotherapy Chemotherapy : No prior systemic chemotherapy metastatic melanoma No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy , interstitial brachytherapy , radiosurgery At least 3 week since prior radiotherapy brain brain metastasis melanoma Prior radiotherapy indicator lesion allow provided recent evidence disease progression site No concurrent radiotherapy Surgery : At least 2 week since prior surgery require general anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>